A Welcome from the Editorial Board
Patient case study: Clinical Presentation of ADA Deficiency
Lymphoproliferative disorders not uncommon in ADA-SCID patients
Short- and medium-term safety profile of ADA-SCID gene therapy described
Vector-transduced cell tracking feasible in gene therapy-treated ADA-SCID patients
Metabolic, not microbial, pathogenesis likely for ADA-SCID lung disease
The annual congress for the European Academy of Allergy and Clinical Immunology.
36th Annual meeting of the European Society for Paediatric Infectious Diseases.
The 26th Anniversary Congress of the European Society for Gene & Cell Therapy.
Question 1: After reviewing the website's content, I am better able to:
Springer Healthcare IME is seeking funding to continue this educational resource for another year. It would help us greatly to assess how the website has helped to extend your knowledge and find out what resources you would like to see in the future.
We would greatly appreciate if you could complete this short survey, taking no more than 5 minutes.
Complete Survey I’ll do it later